ClinicalTrials.gg
Not yet recruitingNCT07685886MIRACLE-T2DUpdated Jul 6, 2026

MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

A Phase 4 interventional study of Montelukast and Placebo in Diabetes, Kidney Disease and Vascular Disease, sponsored by University of Colorado, Denver. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by University of Colorado, Denver · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Diabetes Mellitus by University of Colorado, Denver — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus · University of Colorado, Denver.

Planned enrollment
5th of 34
110 · median 36
Started
2026
with 2 others
Phase 4
6 of 47
2 open now
Registered
47th of 47
by date

Among the 47 studies in Diabetes Mellitus by University of Colorado, Denver, this one is the 5th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 4, and was the 47th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

7 of the 47 studies in Diabetes Mellitus by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Diabetes Mellitus by University of Colorado, Denver, or all of them as a file.
02

Study summary

Diabetes mellitus type 2 is associated with significant morbidity and mortality; and identifying new treatments for diabetes complications to be used alone or in combination with other therapies is a high priority. Hyperglycemia triggers proinflammatory pathways leading to damage in the kidneys, eyes and blood vessels; thus targeting proinflammatory lipid mediators called leukotrienes may represent a promising therapy for diabetes complications. This clinical trial seeks to investigate whether montelukast, a leukotriene antagonist, improves kidney, eye and vascular function in adult participants with type 2 diabetes and kidney disease.

03

Conditions studied

  • Diabetes
  • Kidney Disease
  • Vascular Disease
  • Retinopathy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes type 2
  • Urine albumin to creatinine ratio 30-5000 mg/g
  • CKD stage 2-3 ( 30-89 ml/min/1.73m2)
  • Blood pressure \< 140/90 mmHg prior to randomization
  • \< or = to 40 kg/m2
  • Use of ACEi or ARB with stable dose for 4 weeks
  • if on SGLT2i or GLP-1RA, stable dose for 3 months prior to baseline
  • Able to provide consent

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Uncontrolled hypertension
  • >10%
  • Pregnancy or planning to become pregnant or currently breastfeeding
  • Allergy to aspirin
  • History of major psychiatric disorder
  • Use of inhaled or systemic or long-acting beta agonists
  • Proliferative retinopathy requiring current treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Montelukast

    10 mg capsule by mouth daily

    Drug: Montelukast

  • Placebo comparator
    Placebo

    One matching capsule by mouth daily

    Drug: Placebo

Interventions

  • 10 my by mouth daily

  • DrugPlacebo

    One capsule by mouth daily

06

What researchers measure

Primary outcomes

  1. Change from baseline in urine albumin excretion at 12 months

    24-hour urine albumin

    Time frame: From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. Change from baseline in creatinine clearance at 12 months

    Time frame: From time of enrollment until end of treatment at 12 months

  2. Change from baseline in vascular endothelial function at 12 months

    Measured by brachial artery flow mediated dilation

    Time frame: From enrollment to the end of treatment at 12 months

  3. Change from baseline in arterial stiffness at 12 months

    Measured by aortic pulse wave velocity

    Time frame: From enrollment until end of treatment at 12 months

  4. Change from baseline in diabetic retinopathy at 12 months

    Measured by OCTA

    Time frame: From enrollment until to the end of treatment at 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use. The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use. The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2031, 57 months later.

Of 149 non-industry phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 57 months is above that.

Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jun 30, 2031
CompletionEst.
Aug 31, 2031
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07685886
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jun 30, 2031 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Jul 6, 2026

Study contacts

Jessica Kendrick, MD MPH
Contact
jessica.kendrick@cuanschutz.edu
303-724-4837
Jessica Kendrick, MD MPH
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Montelukast

Start the discussion